Skyhawk Therapeutics
Tracked across 1 events · 7 articles · First seen Jun 30, 2026 · Last active Jun 30, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Skyhawk Therapeutics announced positive 12-month interim data from its Phase 1/2 clinical trial of SKY-0515 for Huntington s disease, showing favorable trends across key metrics and reductions in disease-related proteins. This positive development significantly enhances the company's prospects and validates its SKYSTAR platform.
Jun 30, 2026 · 7 articles
100
Skyhawk Therapeutics released clinical trial dataSkyhawk SKY-0515...
70
Skyhawk Therapeutics enrolled participantsSkyhawk SKY-0515...
ERGEN INTELLIGENCE
Track Skyhawk Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard